FPH - Fisher Paykel Healthcare.

[Panda-NZ-]

Resmed up 10% during last 5 days, 23% for the month.

[kiwiyankee]

here we go again!

https://www.nzherald.co.nz/world/cov...CLN2GGG6FE3BQ/

[Leftfield]

Nice SP action recently.....

Onwards and upwards.

[alokdhir]

May exports data out today . Estimated revenue for FPH comes to $ 179 mil UP 13% PCP

Now we have 2 months for FY 22 which seems to be holding up better then expected ...163 , 179 mil for April and May revenues

[BlackPeter]

May exports data out today . Estimated revenue for FPH comes to $ 179 mil UP 13% PCP

Now we have 2 months for FY 22 which seems to be holding up better then expected ...163 , 179 mil for April and May revenues

Good.

However - it still might be a bit early to praise the year after the first two months of revenue. Whatever is happening currently in the world - linear extrapolation might not be the best method to forecast the future :

Discl: holding a wee parcel and don't mind to buy more if the price is right.

[winner69]

Good.

However - it still might be a bit early to praise the year after the first two months of revenue. Whatever is happening currently in the world - linear extrapolation might not be the best method to forecast the future :

Discl: holding a wee parcel and don't mind to buy more if the price is right.

Maybe he was not thinking linear extrapolation.......and hinting full year could be +80%

Maybe too early to make that call as well

[BlackPeter]

Maybe he was not thinking linear extrapolation.......and hinting full year could be +80%

Maybe too early to make that call as well

I wonder whether they wanted to give us a hint at the AGM when they said that they are not able to provide a forecast ...

[Rawz]

I wonder whether they wanted to give us a hint at the AGM when they said that they are not able to provide a forecast ...

Fairly hard to provide a forecast with all these covid variants, what is it now, delta +? No doubt more to come and more infections?

Also looking to add more, around $29 mark. If it ever drops down there again.

[kiwiyankee]

From FN Arena: https://www.fnarena.com/index.php/20...n-28-2021/#FPH

FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

Medical Equipment & Devices – Overnight Price: $29.31
Goldman Sachs rates ((FPH)) as Buy (1) –
Beyond some near-term dynamics, including the decline in hospitalisations and elevated air freight costs, Goldman Sachs discerns nothing changes the broker's positive mid/long-term view on Fisher & Paykel Healthcare.
Overall, Goldman Sachs updates sales, earnings, and earnings per share forecasts by an average of -8%, -18%, and -18% through FY22-23 as the broker re-bases consumables forecasts to reflect a lower exit-rate and factor in an elevated level of air freight costs.
The broker's FY22-25 earnings forecasts are 4-12% above their pre-pandemic levels.
Although not cheap in absolute terms, Goldman Sachs sees a clear double-digit growth trajectory plus, on a growth-adjusted basis, more valuation support than for other manufacturers.
Buy rating is maintained. Target price is lowered to $33.00 to reflect earnings revisions.
This report was produced on May 27, 2021.
Target price is $33.00 Current Price is $29.31 Difference: $3.69
If FPH meets the Goldman Sachs target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Goldman Sachs forecasts a full year FY22 dividend of 37.23 cents and EPS of 53.05 cents.
At the last closing share price the estimated dividend yield is 1.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.25.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Goldman Sachs forecasts a full year FY23 dividend of 43.75 cents and EPS of 62.36 cents.
At the last closing share price the estimated dividend yield is 1.49%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 47.00.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Jarden rates ((FPH)) as Overweight (2) –
Fisher & Paykel Healthcare has reported a strong FY21 result, with net profit up 82% to NZ$524m, but soft relative to high market expectations, according to Jarden.
The step change in profitability was underpinned by unprecedented covid demand for its hospital division, with the company selling around 6x normal hardware, and circa 2x consumables, while treating 20m patients.
No earnings guidance was provided for FY22, but the company reiterated its NZ$20bn total addressable market estimate. The company also reaffirmed plans to keep advancing manufacturing capacity and hold higher levels of inventory to ensure any surge in demand can be met.
The broker believes covid has materially strengthened the company's growth opportunity, particularly with respect to high nasal flow therapy both with the Hospital and Home setting.
Jarden has amended FY22-24 net profit estimates by -4%, -4%, and 1% but notes the inherent difficulty calibrating what a normalisation profile looks like for the company.
Overweight recommendation maintained, and target price is lowered to NZ$34.00 from NZ$36.10 to reflect Jarden's near-term downgraded forecasts.
The report was issued May 27, 2021.
Current Price is $29.31. Target price not assessed.
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Jarden forecasts a full year FY22 dividend of 42.54 cents and EPS of 65.43 cents.
At the last closing share price the estimated dividend yield is 1.45%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 44.79.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Jarden forecasts a full year FY23 dividend of 48.59 cents and EPS of 74.65 cents.
At the last closing share price the estimated dividend yield is 1.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.27.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

---

Wilsons rates ((FPH)) as Overweight (1) –
While short term earnings visibility remains tough in the absence of quantitative guidance, Wilsons' positive view on Fisher & Paykel Healthcare is based on the broker's analysis of the outlook for the company's high-flow nasal cannula device.
The company's second half result featured a beat on hardware sales, and this momentum will likely continue in emerging markets where covid admissions remain high, the broker suggests.
Consumables sales missed the broker's forecasts but it is impossible to determine whether this reflects a lag in installed base ‘pull-through’ or suboptimal utilisation of units placed during the pandemic, the broker notes.
Overweight retained, target falls to $35.00 from $37.50.
Report first published May 28, 2021.
Target price is $35.00 Current Price is $29.31 Difference: $5.69
If FPH meets the Wilsons target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $30.00, suggesting upside of 2.4%(ex-dividends)
The company's fiscal year ends in March.
Forecast for FY22:
Wilsons forecasts a full year FY22 dividend of 37.23 cents and EPS of 64.78 cents.
At the last closing share price the estimated dividend yield is 1.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 45.25.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.1, implying annual growth of N/A.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 47.2.
Forecast for FY23:
Wilsons forecasts a full year FY23 dividend of 38.16 cents and EPS of 66.27 cents.
At the last closing share price the estimated dividend yield is 1.30%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 44.23.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.8, implying annual growth of 1.1%.
Current consensus DPS estimate is 40.7, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 46.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

[Rawz]

Thanks for posting Kiwiyankee.

"clear double-digit growth trajectory"
"covid has materially strengthened the company's growth opportunity, particularly with respect to high nasal flow therapy both with the Hospital and Home setting."

Brokers all got their estimates wrong. I won't bother. Happy to keep buying on any share price weakness, around $29 seems to be working. Has popped down there a few times then bounced back to the low $30's.

Hold for long long term. Can't go wrong? Don't think ill regret holding these come 2030.. 2040